Amelioration of chemotherapy-induced intestinal mucositis by orally administered probiotics in a mouse model

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Yeung, Chun Yan ^a,b,c   Chan, Wai Tao ^a   Jiang, Chun Bin ^a   Cheng, Mei Lien ^a   Liu, Chia Yuan ^a   Chang, Szu Wen ^a   Chiau, Jen Shiu Chiang ^a   Lee, Hung Chang ^a,d  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b MACKAY MEDICAL COLLEGE   (Taiwan)

^c NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIFIDOBACTERIUM BIFIDUM; BLOOD SAMPLING; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; ENTEROPATHY; GENE EXPRESSION REGULATION; GOBLET CELL; IL 1BETA GENE; IL 6 GENE; INTESTINAL MUCOSITIS; INTESTINAL VILLUS HEIGHT; INTESTINE CRYPT DEPTH; INTESTINE PARAMETERS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; MALE; MOUSE; MOUSE MODEL; MUCOSA INFLAMMATION; NONHUMAN; PROTEIN BLOOD LEVEL; SCORING SYSTEM; TNF ALPHA GENE; UPREGULATION; WEIGHT CHANGE; ANIMAL; BIFIDOBACTERIUM; BLOOD; CHEMICALLY INDUCED; DIET THERAPY; DISEASE MODEL; DRUG EFFECTS; GENETICS; INTESTINE MUCOSA; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHYSIOLOGY;

ADMINISTRATION, ORAL; ANIMALS; BIFIDOBACTERIUM; CYTOKINES; DIARRHEA; DISEASE MODELS, ANIMAL; FLUOROURACIL; GENE EXPRESSION REGULATION; INTESTINAL MUCOSA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; MICE; MUCOSITIS; PROBIOTICS;

EID: 84947762368     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138746     Document Type: Article

References (48)

1. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer 2003;3(5):330-8.
2. Smith CL, Geier MS, Yazbeck R, Torres DM, Butler RN, Howarth GS. Lactobacillus fermentum BR11 and fructo-oligosaccharide partially reduce jejunal inflammation in a model of intestinal mucositis in rats. Nutr Cancer 2008;60:757-67.
3. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004;100(9 Suppl):1995-2025.
4. Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG. Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis Colon Rectum 2004;47(9):1519-25.
5. Maioli TU, de Melo Silva B, Dias MN, Paiva NC, Cardoso VN, Fernandes SO, et al. Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice. J Neg Results Biomed 2014;13:6.
6. Gibson RJ, Keefe DM, Lalla RV, Bateman E, Blijlevens N, Fijlstra M, et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Supp Care Cancer 2013;21(1):313-26.
7. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004;100(9 Suppl):2026-46.
8. Bhatt V, Vendrell N, Nau K, Crumb D, Roy V. Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation. J Oncol Pharm Pract 2010;16(3):195-204.
9. Joint FAO/WHO Expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria (2001). FAO Food and Nutrition paper 85, 1-50.
10. Bellavia M. Lactobacillus casei and Bifidobacterium lactis supplementation reduces tissue damage of intestinal mucosa and liver after 2, 4, 6-trinitrobenzenesulfonic acid treatment in mice. J Biol Regul Homeost Agents 2014 28(2):251-61.
11. Geier MS, Butler RN, Giffard PM, Howarth GS. Lactobacillus fermentum BR11, a potential new probiotic, alleviates symptoms of colitis induced by dextran sulfate sodium (DSS) in rats. Int J Food Microbiol 2007;114(3):267-74.
12. Mauger CA, Butler RN, Geier MS, Tooley KL, Howarth GS. Probiotic effects on 5-fluorouracil-induced mucositis assessed by the sucrose breath test in rats. Dig Dis Sci 2007;52(3):612-9.
13. van Vliet MJ, Harmsen HJM, de Bont ESJM, Tissing WJE. The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. Plos Pathog 2010;6:e1000879.
14. Fang SW, Fang SB, Chiang Chiau JS, Yeung CY, Chan WT, Jiang CB, et al. Inhibitory effects of Lactobacillus casei subsp. rhamnosus on Salmonella lipopolysaccharide induced inflammation and epithelial barrier dysfunction in a co-culture model using Caco-2/peripheral blood mononuclear cells. J Med Microbiol 2010;59:573-9.
15. Yeung CY, Chiang Chiau JS, Chan WT, Cheng ML, Liu HL, Lee HC. In vitro prevention of Salmonella lipopolysaccharide-induced damages in epithelial barrier function by various lactobacillus strains. Gastroent Res Pract 2013;973209.
16. Huang TY, Chu HC, Lin TL, Ho WH, Hou HS, Chao YC, et al., Minocycline attenuates 5-fluorouracilinduced small intestinal mucositis in mouse model. Biochem Biophys Res Commun 2009 Nov. 27;389(4):634-9.
17. Bowen JM, Stringer AM, Gibson RJ. VSL# 3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther 2007;6:1449-54.
18. Stringer M, Gibson RJ, Logan RM. Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med 2009 Apr; 234(4):430-41.
19. Maldonado Galdeano C, Novotny Núñez I, de Moreno de LeBlanc A, Carmuega E, Weill R, Perdigón G. Impact of a probiotic fermented milk in the gut ecosystem and in the systemic immunity using a nonsevere protein-energy-malnutrition model in mice. BMC Gastroenterol 2011 May 26;11:64.
20. Takiue S, Akiuoshi H. Light and scanning electron microscope examination of the digestive tract in peppered moray eel, Gymnothorax pictus (Elopomorpha). Anat Rec 2013;296:443-451.
21. Haisan A, Rogojanu R, Croitoru C. Digital microscopy assessment of angiogenesis in different breast cancer compartments. Biomed Res Int 2013;2013:286902. doi: 10.1155/2013/286902 Epub 2013 Sep. 1.
22. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008;57:1470-81.
23. Wagner AE, Boesch-Saadatmandi C, Dose J. Anti-inflammatory potential of allyl-isothiocyanate-role of Nrf2, NF-(kappa) B and microRNA-155. J Cell Mol Med 2012;16:836-43.
24. Wang S, Miller B, Matthan NR, Goktas Z, Wu D, Reedet DB, et al. Aortic cholesterol accumulation correlates with systemic inflammation but not hepatic and gonadal adipose tissue inflammation in low-density lipoprotein receptor null mice. Nutr Res 2013;33:1072-82.
25. Noto Llana M, Sarnacki SH, Aya Castaneda Mdel R, Bernal MI, Giacomodonato MN, Cerquetti MC. Consumption of Lactobacillus casei fermented milk prevents Salmonella reactive arthritis by modulating IL-23/IL-17 expression. Plos One 2013;8:e82588.
26. Carasi P, Díaz M, Racedo SM. Safety characterization and antimicrobial properties of kefir-isolated Lactobacillus kefiri. Biomed Res Int 2014;2014:208974. doi: 10.1155/2014/208974 Epub 2014 May 13.
27. Lalla RV, Peterson DE. Treatment of mucositis, including new medications. Cancer J 2006;12(5):348-54.
28. Goldberg Arnold RJ, Gabrail N, Raut M, Kim R, Sung JCY, Zhou Y. Clinical Implications of Chemotherapy-induced Diarrhea in Patients With Cancer. J Support Oncol 2005;3:227-232.
29. Prisciandaro LD, Geier MS, Butler RN. Evidence supporting the use of probiotics for the prevention and treatment of chemotherapy-induced intestinal mucositis. Crit Rev Food Sci 2011;51:239-47.
30. Whitford EJ, Cummins AG, Butler RN, Prisciandaro LD, Fauser JK, Yazbeck R, et al. Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent, 5-Fluorouracil (5-FU). Cancer Bio Therapy 2009;8(6):505-11.
31. Wadler S, Benson AB, Engelking C, Catalano R, Field M, Kornblau SM, et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 1998;16:3169-78.
32. Benson AB, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Onco 2004;22(14):2918-26.
33. Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Investigational New Drugs 2000;18:299-313.
34. Soares PM, Mota JM, Gomes AS. Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution. Cancer Chemoth Pharm 2008;63:91-8.
35. Sonis ST. The pathobiology of mucositis. Nature Rev Cancer 2004;4(4):277-84.
36. Tazuke Y, Maeda K, Wasa M, Satoko N, Fukuzawa M. Protective mechanism of glutamine on the expression of proliferating cell nuclear antigen after cisplatin-induced intestinal mucosal injury. Pediatr Surg Int 2011;27:151-8.
37. Abimosleh SM, Lindsay RJ, Butler RN, Cummins AG, Howarth GS. Emu oil increases colonic crypt depth in a rat model of ulcerative colitis. Digest Dis Sci 2012;57:887-96.
38. Robbe C, Capon C, Coddeville B, Michalski JC. Structural diversity and specific distribution of O-glycans in normal human mucins along the intestinal tract. Biochem J 2004;384:307-316. [15361072]
39. Leiper K, Campbell BJ, Jenkinson MD. Interaction between bacterial peptides, neutrophils and goblet cells: a possible mechanism for neutrophil recruitment and goblet cell depletion in colitis. Clin Sci 2001;101:395-402. [11566077]
40. Liong MT. Safety of probiotics: Translocation and infection. Nutr Rev 2008;66(4):192-202. doi: 10. 1111/j.1753-4887.2008.00024.x PMID: 18366533
41. Wassenarr TM, Klein G. Safety aspects and implications of regulation of probiotic bacteria in food and food supplements. J Food Prot 2008;71(8):1734-1741. PMID: 18724773
42. Honeycutt TC, Khashab M, Wardrop RM, McNeal-Trice K, Honeycutt ALB, Christy CG, et al. Probiotic administration and the incidence of nosocomial infection in pediatric intensive care: a randomized placebo-controlled trial. Pediatr Crit Care Med 2007;8:452-458.
43. Casey PG, Gardiner GE, Casey G, Bradshaw B, Lawlor PG, Lynch PB, et al. A five-strain probiotic combination reduces pathogen shedding and alleviates disease signs in pigs challenged with Salmonella enterica Serovar Typhimurium. App Environ Microbiol 2007;73(6):1858-63. Epub 2007/01/31. doi: 10.1128/AEM.01840-06
44. Khailova L, Dvorak K, Arganbright KM, Halpern MD, Kinouchi T, Yajima M, et al. Bifidobacterium bifidum improves intestinal integrity in a rat model of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 2009;297(5):G940-9.
45. Ewaschuk JB, Diaz H, Meddings L, Diederichs B, Dmytrash A, Backer J, et al. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am J Physiol Gastrointest Liver Physiol 2008;295:G1025-34.
46. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007;109:820-31.
47. Mauger CA, Butler RN, Geier MS, Tooley KL, Howarth GS. Probiotic effects on 5-fluorouracil-induced mucositis assessed by the sucrose breath test in rats. Digest Dis Sci 2007;52:612-9.
48. Prisciandaro LD, Geier MS, Chua AE, Butler RN, Cummins AG, Sander GR, et al. Probiotic factors partially prevent changes to caspases 3 and 7 activation and transepithelial electrical resistance in a model of 5-fluorouracil-induced epithelial cell damage. Support Care Cancer 2012;20:3205-10.